Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Viral targets for vaccines against COVID-19
Lianpan Dai, George F. Gao
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 73-82
Open Access | Times Cited: 1050

Showing 1-25 of 1050 citing articles:

SARS-CoV-2 variants, spike mutations and immune escape
William T. Harvey, Alessandro M. Carabelli, Ben Jackson, et al.
Nature Reviews Microbiology (2021) Vol. 19, Iss. 7, pp. 409-424
Open Access | Times Cited: 3370
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 706
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination
Rishi R. Goel, Sokratis A. Apostolidis, Mark M. Painter, et al.
Science Immunology (2021) Vol. 6, Iss. 58
Open Access | Times Cited: 652
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Jiahui Chen, Rui Wang, Nancy Benovich Gilby, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 2, pp. 412-422
Open Access | Times Cited: 639
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, et al.
The Lancet Infectious Diseases (2021) Vol. 21, Iss. 8, pp. 1107-1119
Open Access | Times Cited: 419
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
Lok Bahadur Shrestha, Charles S. P. Foster, William D. Rawlinson, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 5
Open Access | Times Cited: 406
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
Jiří Zahradník, Shir Marciano, Maya Shemesh, et al.
Nature Microbiology (2021) Vol. 6, Iss. 9, pp. 1188-1198
Open Access | Times Cited: 377
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 326
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Yingzhu Li, Rumiana Tenchov, Jeffrey Smoot, et al.
ACS Central Science (2021) Vol. 7, Iss. 4, pp. 512-533
Open Access | Times Cited: 316
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 189-199
Open Access | Times Cited: 272
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
Sam Afkhami, Michael R. D’Agostino, Ali Zhang, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 896-915.e19
Open Access | Times Cited: 264
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
Allison J. Greaney, Andrea N. Loes, Lauren E. Gentles, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 600
Open Access | Times Cited: 239
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
Yongfei Cai, Jun Zhang, Tianshu Xiao, et al.
Science (2021) Vol. 373, Iss. 6555, pp. 642-648
Open Access | Times Cited: 236
Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
Lianpan Dai, Lidong Gao, Lifeng Tao, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 22, pp. 2097-2111
Open Access | Times Cited: 222
Role of nanotechnology behind the success of mRNA vaccines for COVID-19
Amit Khurana, Prince Allawadhi, Isha Khurana, et al.
Nano Today (2021) Vol. 38, pp. 101142-101142
Open Access | Times Cited: 220
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
Christoph Jung, Dorota Kmieć, Lennart Koepke, et al.
Journal of Virology (2022) Vol. 96, Iss. 6
Open Access | Times Cited: 202
Structure of SARS-CoV-2 spike protein
Jun Zhang, Tianshu Xiao, Yongfei Cai, et al.
Current Opinion in Virology (2021) Vol. 50, pp. 173-182
Open Access | Times Cited: 187
COVID-19 vaccination: The road ahead
Daniel M. Altmann, Rosemary J. Boyton
Science (2022) Vol. 375, Iss. 6585, pp. 1127-1132
Closed Access | Times Cited: 180
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Michael J. Hogan, Norbert Pardi
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 17-39
Open Access | Times Cited: 177
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
Gary R. McLean, Jeremy P. Kamil, Benhur Lee, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 174
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Donal Skelly, Adam Harding, Javier Gilbert‐Jaramillo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 168
The glycosylation in SARS-CoV-2 and its receptor ACE2
Yanqiu Gong, Suideng Qin, Lunzhi Dai, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 166
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy
Azizul Haque, Anudeep B. Pant
Journal of Autoimmunity (2022) Vol. 127, pp. 102792-102792
Open Access | Times Cited: 164
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
Pan-Pan Zhou, Meng Yuan, Ge Song, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 637
Open Access | Times Cited: 160
Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies
Yifan Wang, Caixuan Liu, Chao Zhang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 155
Page 1 - Next Page

Scroll to top